Wire by Fusion42
Fusion42 Scout Raise
The Debrief & Outliers
Regulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers
Benchmarks
Benchmarks HomeBy News TypeBy RegionBy Sector
AI WeeklyAbout

Switch product

Fusion42RaiseScoutWire

The Debrief & Outliers

All editionsRegulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers

Database & benchmarks

Benchmarks HomeBy News TypeBy RegionBy SectorStories

Account

Sign in
← Back

Wire · opportunities

US Alzheimer's Blood Test Battle Begins With Roche, C2N FDA Clearence

26 August 2026 · By · Wire by Fusion42

Published

26 August 2026

Topic

opportunities

◆ Sectors

Medtech

◆ Geography

United States

◆ Source

Read at insights.citeline.com →

◆ Verified

Fusion42 · 27 August 2026 · Fusion42 review

The FDA has cleared Alzheimer's blood tests from Roche and C2N Diagnostics, initiating a competition in the US market for earlier and less invasive Alzheimer’s diagnosis.

This Wire brief sits within Fusion42's coverage of Medtech.

◆ ◆ The Wire takeaway

Alzheimer’s diagnostics just opened to new players with FDA clearances clearing the way for blood tests as alternatives to imaging. You in medtech should plan for a fast-shifting diagnostic standard and new payer conversations.

◆ Coverage

1 source · 26 Aug 2026

◆ Related on Wire

◆ Topics

Medtechalzheimersfda-clearancemedtechdiagnosticsus-market